- World first patents claimed by us in 15 patent applications
- These discoveries strengthen MindBio’s commercialization pipeline for non-invasive detection of neuroactive substances using voice and AI.
- MindBio is on track to deliver its first commercial prototype this quarter.
VANCOUVER, British Columbia, June 4, 2026 (GLOBE NEWSWIRE) — MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF); (“”company ” or “mind bio ”), a biotechnology company commercializing AI-driven speech analytics for drug and alcohol intoxication detection, is pleased to announce that the company has launched its flagship commercial validation and testing software, Intox AI™.
Intox AI™, MindBio’s enterprise solution for intoxication and fatigue detection, enables new analytical capabilities to detect cocaine, cannabis, alcohol, psychedelic, drug use, and human fatigue in audio. Intox AI™ changes the category of drug use and fatigue detection in high-risk industries where sobriety and alertness are essential health and safety requirements to save lives. This technology will be implemented in Edge AI kiosks, with the first prototype production expected to be completed soon. The company is targeting commercialization in industries where there is pressure to expand drug and alcohol testing and where testing is mandated by regulators, such as mining, aviation, construction, heavy transportation, and law enforcement, and where large-scale mass testing for a variety of drugs, alcohol, and human fatigue poses a major operational challenge.
Current drug and alcohol testing systems include mouth swab tests and breathalyzers. These tests are time consuming, costly per test, unhygienic and environmentally harmful due to high plastic usage and waste. MindBio’s voice AI solution aims to quickly scan for poisoning and remove these issues from traditional drug testing procedures. MindBio’s solutions aim to increase efficiency and enable testing at scale, which is not possible with current systems.
“The launch of Intox AI™ is a major advancement for drug and alcohol testing across a variety of substances that impact human performance and safety,” said Justin Hanka, CEO of the company. “We are on track to deliver our first prototype testing kiosks soon and are pleased that our core software is ready for testing and validation.”
For more information, please contact us below.
Justin Hanka, CEO
+61 433140886
justin@mindbiotherapeutics.com
www.mindbiotherapeutics.com
About MindBio Therapeutics Corp.
MindBio is a biotechnology company commercializing AI predictive technology for drug and alcohol addiction detection through voice analysis across a variety of substances. Using millions of data points analyzed in real-time and seconds, an AI predictive model predicts drunkenness and fatigue with incredible accuracy, just using the human voice. The company is developing an enterprise platform that includes Edge-AI kiosks, which integrate bespoke hardware and software to detect drug and alcohol intoxication using human voice and AI in various enterprise environments such as mining, aviation, construction, and law enforcement.
Cautionary Note Regarding Forward-Looking Statements:
The press release contains “forward-looking statements” within the meaning of applicable securities laws, including, but not limited to, our ability to complete the offering and option grant in accordance with the announced terms and the development of a voice and AI-powered enterprise platform for use in drug and alcohol intoxication detection. Forward-looking statements include “anticipate,” “intend,” “plan,” “budget,” “believe,” “anticipate,” “estimate,” “expect,” “planned,” “predict,” “strategy,” They can be identified by words such as “will”, “likely”, “may”, “will”, “could”, “will”, “should”, “will” and similar references to the future. periods, negative or similar terms, and terms commonly used in the future and conditions. Forward-looking statements are based on assumptions as of the date they are made. However, there can be no assurance that such assumptions will reflect the actual results of such items or factors.
In addition, there are known and unknown risk factors that may cause our actual results of operations and financial condition to differ materially from those expressed in the forward-looking statements. Therefore, you should not rely on these forward-looking statements. Important risk factors that could cause actual results and financial condition to differ materially from those expressed in the forward-looking statements include: the risk that the Company may not be able to raise the gross proceeds from the offering; failure to obtain final regulatory approval; technical challenges in developing or deploying enterprise platforms; general economic, market and business conditions in Canada and Australia; market volatility. There may be unexpected delays in the timeline of transactions or events described in this press release. All forward-looking information is qualified in its entirety by this cautionary statement.
The Company undertakes no obligation to revise or update such forward-looking statements to reflect future results, events or developments or to publicly release any revisions to the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of the information in this press release.
